Literature DB >> 16707724

CYP4 isoform specificity in the omega-hydroxylation of phytanic acid, a potential route to elimination of the causative agent of Refsum's disease.

Fengyun Xu1, Valerie Y Ng, Deanna L Kroetz, Paul R Ortiz de Montellano.   

Abstract

The saturated C20 isoprenoid phytanic acid is physiologically derived from phytol released in the degradation of chlorophyll. The presence of a C-3 methyl group in this substrate blocks normal beta-oxidation, so phytanic acid degradation primarily occurs by initial peroxisomal alpha-oxidation to shift the register of the methyl group. However, individuals with Refsum's disease are genetically deficient in the required phytanoyl-CoA alpha-hydroxylase and suffer from neurological pathologies caused by the accumulation of phytanic acid. Recent work has shown that phytanic acid can also be catabolized by a pathway initiated by omega-hydroxylation of the hydrocarbon chain, followed by oxidation of the alcohol to the acid and conventional beta-oxidation. However, the enzymes responsible for the omega-hydroxylation of phytanic acid have not been identified. In this study, we have determined the activities of all of the rat and human CYP4A enzymes and two of the rat CYP4F enzymes, with respect to the omega-hydroxylation of phytanic acid. Furthermore, we have shown that the ability to omega-hydroxylate phytanic acid is elevated in microsomes from rats pretreated with clofibrate. The results support a possible role for CYP4 enzyme elevation in the elimination of phytanic acid in Refsum's disease patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707724     DOI: 10.1124/jpet.106.104976

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

Review 1.  Structural control of cytochrome P450-catalyzed ω-hydroxylation.

Authors:  Jonathan B Johnston; Hugues Ouellet; Larissa M Podust; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2010-08-19       Impact factor: 4.013

Review 2.  Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism.

Authors:  Paul P Van Veldhoven
Journal:  J Lipid Res       Date:  2010-06-17       Impact factor: 5.922

3.  CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.

Authors:  Matthew G McDonald; Mark J Rieder; Mariko Nakano; Clara K Hsia; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2009-03-18       Impact factor: 4.436

4.  Biochemical and structural characterization of CYP124: a methyl-branched lipid omega-hydroxylase from Mycobacterium tuberculosis.

Authors:  Jonathan B Johnston; Petrea M Kells; Larissa M Podust; Paul R Ortiz de Montellano
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-20       Impact factor: 11.205

5.  Differential Regulation of Gene Expression by Cholesterol Biosynthesis Inhibitors That Reduce (Pravastatin) or Enhance (Squalestatin 1) Nonsterol Isoprenoid Levels in Primary Cultured Mouse and Rat Hepatocytes.

Authors:  Elizabeth A Rondini; Zofia Duniec-Dmuchowski; Daniela Cukovic; Alan A Dombkowski; Thomas A Kocarek
Journal:  J Pharmacol Exp Ther       Date:  2016-05-25       Impact factor: 4.030

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.